补充维生素D3对维生素D缺乏女性有症状子宫肌瘤的影响。
Effect of Vitamin D3 Supplementation on Symptomatic Uterine Leiomyoma in Women with Hypovitaminosis D.
作者信息
Suneja Amita, Faridi Fahmina, Bhatt Shuchi, Guleria Kiran, Mehndiratta Mohit, Sharma Richa
机构信息
Department of Gynecology and Obstetrics, University College of Medical Sciences and GTB Hospital, University of Delhi, Delhi, India.
Department of Radiology, University College of Medical Sciences and GTB Hospital, University of Delhi, Delhi, India.
出版信息
J Midlife Health. 2021 Jan-Mar;12(1):53-60. doi: 10.4103/jmh.JMH_90_19. Epub 2021 Apr 17.
OBJECTIVE
The objective of this study is to evaluate the effect of Vitamin D3 on symptoms, uterine and leiomyoma volume in women with symptomatic leiomyoma and hypovitaminosis D.
MATERIALS AND METHODS
In this pilot, interventional, prospective study, 30 premenopausal women with uterine leiomyoma and concomitant hypovitaminosis D (<30 ng/ml) received Vitamin D3 in doses of 60,000 IU weekly for 8 weeks followed by 60,000 IU every 2 weeks for another 8 weeks. Change in symptoms, uterine, and leiomyoma volume was evaluated at 8 weeks and 16 weeks. Serum Vitamin D3 levels were repeated at 16 weeks of therapy.
RESULTS
A significant negative correlation was observed between the baseline 25-hydroxy Vitamin D (25(OH) Vitamin D3) and leiomyoma volume ( = -0.434, < 0.001). There was significant reduction of menstrual blood loss by 29.89% ( = 0.003) and severity of dysmenorrhea, pelvic pain, and backache by 44.12%, 35%, and 50% ( < 0.001, 0.019, and 0.002), respectively, at 16 weeks. At end of therapy, there was 6% reduction in mean uterine volume and 11% in leiomyoma volume which was not significant. Serum 25(OH) Vitamin D was significantly higher than baseline level (17.44 ± 5.82 vs. 39.38 ± 8.22, < 0.001) at end of therapy.
CONCLUSION
Vitamin D3 supplementation is effective in reducing leiomyoma-related symptoms and stabilizing uterine and leiomyoma volume.
目的
本研究旨在评估维生素D3对有症状的平滑肌瘤且维生素D缺乏的女性的症状、子宫及平滑肌瘤体积的影响。
材料与方法
在这项前瞻性干预性试验研究中，30名患有子宫平滑肌瘤且伴有维生素D缺乏（<30 ng/ml）的绝经前女性，每周接受60,000 IU的维生素D3治疗，持续8周，随后每2周接受60,000 IU，再持续8周。在第8周和第16周评估症状、子宫及平滑肌瘤体积的变化。治疗16周时重复检测血清维生素D3水平。
结果
观察到基线25羟维生素D（25(OH)维生素D3）与平滑肌瘤体积之间存在显著负相关（r = -0.434，P < 0.001）。在第16周时，月经出血量显著减少29.89%（P = 0.003），痛经、盆腔疼痛和背痛的严重程度分别降低44.12%、35%和50%（P < 0.001、0.019和0.002）。治疗结束时，平均子宫体积减少6%，平滑肌瘤体积减少11%，但差异无统计学意义。治疗结束时血清25(OH)维生素D显著高于基线水平（17.44 ± 5.82 vs. 39.38 ± 8.22，P < 0.001）。
结论
补充维生素D3可有效减轻平滑肌瘤相关症状，并稳定子宫及平滑肌瘤体积。
Zotero 插件